Free Trial
NASDAQ:PMVP

PMV Pharmaceuticals (PMVP) Stock Price, News & Analysis

PMV Pharmaceuticals logo
$1.21 +0.11 (+10.00%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$1.21 0.00 (0.00%)
As of 07/3/2025 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About PMV Pharmaceuticals Stock (NASDAQ:PMVP)

Key Stats

Today's Range
$1.06
$1.19
50-Day Range
$0.84
$1.21
52-Week Range
$0.81
$1.82
Volume
582,828 shs
Average Volume
197,978 shs
Market Capitalization
$62.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50
Consensus Rating
Buy

Company Overview

PMV Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

PMVP MarketRank™: 

PMV Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 1819th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PMV Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    PMV Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about PMV Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for PMV Pharmaceuticals are expected to decrease in the coming year, from ($1.06) to ($1.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PMV Pharmaceuticals is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PMV Pharmaceuticals is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    PMV Pharmaceuticals has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about PMV Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.99% of the float of PMV Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    PMV Pharmaceuticals has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PMV Pharmaceuticals has recently increased by 1.69%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    PMV Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    PMV Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.99% of the float of PMV Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    PMV Pharmaceuticals has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PMV Pharmaceuticals has recently increased by 1.69%, indicating that investor sentiment is decreasing.
  • News Sentiment

    PMV Pharmaceuticals has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for PMV Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for PMVP on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, PMV Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $121,505.00 in company stock.

  • Percentage Held by Insiders

    Only 7.57% of the stock of PMV Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    90.20% of the stock of PMV Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about PMV Pharmaceuticals' insider trading history.
Receive PMVP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PMV Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PMVP Stock News Headlines

Pmv Pharmaceuticals Inc (PMVP) - Investing.com
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it takes for the entire thing to burn right up. It’s a NEW internet service poised to disrupt the entire $3.2 trillion telecom industry. But you may only have this chance if you act before December 31st, 2025.
PMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)
See More Headlines

PMVP Stock Analysis - Frequently Asked Questions

PMV Pharmaceuticals' stock was trading at $1.51 at the beginning of the year. Since then, PMVP shares have decreased by 19.9% and is now trading at $1.21.

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) issued its quarterly earnings data on Friday, May, 9th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.03.

PMV Pharmaceuticals (PMVP) raised $126 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO.

Shares of PMVP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PMV Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), NIO (NIO), Meta Platforms (META), Plug Power (PLUG), Aptose Biosciences (APTO), Clean Energy Fuels (CLNE) and Intel (INTC).

Company Calendar

Last Earnings
5/09/2025
Today
7/04/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PMVP
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$6.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+354.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$58.71 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.40 per share
Price / Book
0.36

Miscellaneous

Free Float
48,020,000
Market Cap
$62.86 million
Optionable
Optionable
Beta
1.49
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:PMVP) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners